Antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis associated to the use of propylthiouracil. Report of four cases;Vasculitis ANCA-positivo en pacientes hipertiroideos usuarios de propiltiouracilo

Revista Medica de Chile

Volumn 134, Issue 4, 2006, Pages 475-480

  Hidalgo V, Soledad ^a,b   Silva A, Paulina ^a   Undurraga S, Fernanda ^a   Soto I, Néstor ^a   Marinovic M, María Angélica ^a  

^a HOSPITAL SAN BORJA ARRIARÁN   (Chile)

^b NONE

Author keywords

Antibodies, antineutrophil cytoplasmic; Propylthiouracil; Vasculitis

Indexed keywords

EID: 33744469316     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. CHOI H, MERKEL P, WALKER A, NILES J. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis. Arthritis rheum 2000; 43: 405-13.
2. KALLENBERG CG, MULDER AH, TELVAERT JW. Antineutrophil cytoplasmic antibodies: A still-growing class of autoantibodies in inflammatory disorders. Am J Med 1992; 93: 675-82.
3. VASSILOPOULOS D, HOFFMAN G. Clinical Utility for Antineutrophil Cytoplasmic Antibodies. Clinical and Diagnostic Laboratory and Immunology 1999; 6: 645-51.
4. STANKUS SJ, JOHNSON NT. Propylthiouracil-induced hypersensitivity vasculitis presenting as respiratory failure. Chest 1992; 102: 1595-6.
5. GUNTON JE, STIEL J, CATERSON RJ, MCELDUFF A. Clinical Case Seminar. J Clin Endocrinol Metab 1999; 84: 13-6.
6. SCULLY R. Case Records of the Massachusetts General Hospital. N Engl J Med 2001; 345: 981-6.
7. LEE HARRIS N. Case Records of the Massachusetts General Hospital. N Engl J Med 2002; 347: 122-30.
8. YUASA S, HASHIMOTO M, YURA T, SUMIKURA T, TAKAHASHI N, SHOJI T ET AL. Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Crescentic Glomerulonephritis and Propylthiouracil Therapy. Nephron 1996; 73: 701-3.
9. DHILLON S, SINGH D, DOE N, QADRI A, RICCIARDI S, SCHWARZ M. Diffuse Alveolar Hemorrhage and Pulmonary Capillaritis Due to Propylthiouracil. Chest 1999; 116: 1485-8.
10. SATO H, HATTORI M, FUJIEDA M, SUGIHARA S, INOMATA H, HOSHI M ET AL. High Prevalence of Antineutrophil Cytoplasmic Antibody Positivity in Childhood Onset Graves' Disease Treated with Propylthiouracil. J Clin Endocrinol Metab 2000; 85: 4270-3.
11. JENNETTE JC, FALK RJ. Small Vessel Vasculitis. N Eng J Med 1997; 337: 1512-23.
12. EKENSTAM E, CALLEN JP. Cutaneous leukocytoclastic vasculitis: clinical and laboratory features of 82 patients seen in private practice. Arch Dermatol 1984; 120: 484-9.
13. SÁNCHEZ NP, VAN HALE HM, SU WPD. Clinical and histopathologic spectrum of necrotizing vasculitis: report of findings in 101 cases. Arch Dermatol 1985; 121: 220-4.
14. GUNTON J, STIEL J, CLIFTON-BLIGH P, WILMSHURST E, MCELDUFF A. Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication. European Journal of Endocrinol 2000; 142: 587-90.
15. LAM DCC, LINDSAY RH. Accumulation of 2-{14C} propylthiouracil in human polymorphonuclear leukocytes. Biochem Pharmacol 1979; 28: 2151-3.
16. LEE H, HIROUCHI M, HOSOKAWA M, SAYO H, KOHNO M, KARIYA K. Inactivation of peroxidase of rat bone marrow by repeated administration of propylthiouracil is accompanied by a change in the heme structure. Biochem Pharmacol 1998; 37: 2151-3.
17. LEE E, MIKI Y, KATSURA H, KARIYA K. Mechanism of Inactivation of Myeloperoxidase by Propylthiouracil. Biochem Pharmacol 1990; 39: 1467-71.
18. KITAHARA T, HIROMURA K, MAEZAWA A, ONO K, NARAHARA N, YANO S ET AL. Case of propylthiouracil-induced vasculitis associated with anti-neutrophil cytoplasmic antibody (ANCA); review of literature. Clinical Nephrology 1997; 47: 336-40.
19. SERA N, ASHIZAWA K, TAKAO A, ABE Y, IDE A, USA T ET AL. Treatment with Propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease. Thyroid 2000; 10: 595-9.
20. PARK KE, CHIPPS D, BENSON E. Necrotizing vasculitis secondary to PTU presenting as purpura fulminans. Rheumatology 1999; 38: 790-2.